Lexeo Therapeutics (LXEO) Income towards Parent Company: 2022-2023
Historic Income towards Parent Company for Lexeo Therapeutics (LXEO) over the last 1 years, with Dec 2023 value amounting to -$14.2 million.
- Lexeo Therapeutics' Income towards Parent Company rose 2.68% to -$14.2 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$66.4 million, marking a year-over-year change of. This contributed to the annual value of -$98.3 million for FY2024, which is 48.11% down from last year.
- As of Q4 2023, Lexeo Therapeutics' Income towards Parent Company stood at -$14.2 million, which was up 29.45% from -$20.1 million recorded in Q3 2023.
- In the past 5 years, Lexeo Therapeutics' Income towards Parent Company ranged from a high of -$13.4 million in Q2 2023 and a low of -$20.1 million during Q3 2023.
- For the 2-year period, Lexeo Therapeutics' Income towards Parent Company averaged around -$16.3 million, with its median value being -$15.8 million (2022).
- Within the past 5 years, the most significant YoY rise in Lexeo Therapeutics' Income towards Parent Company was 2.68% (2023), while the steepest drop was 17.90% (2023).
- Over the past 2 years, Lexeo Therapeutics' Income towards Parent Company (Quarterly) stood at -$14.6 million in 2022, then rose by 2.68% to -$14.2 million in 2023.
- Its Income towards Parent Company was -$14.2 million in Q4 2023, compared to -$20.1 million in Q3 2023 and -$13.4 million in Q2 2023.